化合物LFM-A13 T6217
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 7
- 0
Product IntroductionBioactivity英文名: LFM-A13描述: LFM-A13 是一种 BTK，JAK2，PLK 有效抑制剂，可抑制 BTK、Plx1 和 PLK3 的活性，IC50分别为 2.5、10 和 61
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: LFM-A13
描述: LFM-A13 是一种 BTK，JAK2，PLK 有效抑制剂，可抑制 BTK、Plx1 和 PLK3 的活性，IC50分别为 2.5、10 和 61 μM。
体外活性: In BTK+ B-lineage leukemic cells, LFM-A13 enhances their sensitivity to ceramide- or vincristine-induced apoptosis. [1] In BCL-1 cells, NALM-6 cells, or normal BALB/c splenocytes, LFM-13 inhibits the enzymatic activity of BTK in BCL-1 cells without affecting the BTK protein expression levels [2] In human neutrophils, LFM-A13 decreases the tyrosine phosphorylation induced by fMet-Leu-Phe and inhibits the production of superoxide anions and the stimulation of adhesion, chemotaxis, and phospholipase D activity. [3]
体内活性: In BALB/c mice bearing BCL-1 leukemia, combination of LFM-A13 (50 mg/kg/day i.p.) and the standard triple-drug VPL prolongs the median survival time. [2] In primary myeloma-bearing SCID-rab mice, LFM-A13 inhibits osteoclast activity, prevents myeloma-induced bone resorption and suppresss myeloma growth. [4]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 67 mg/mL (186.1 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字: Janus kinase | JAK | LFM-A-13 | Inhibitor | LFMA13 | Polo-like Kinase (PLK) | Bruton tyrosine kinase | Btk | LFM A13 | inhibit | LFM-A13
相关产品: HMN-176 | MLN0905 | TAK-960 | Onvansertib | PHA-680632 | 7-O-Prenylscopoletin | 3MB-PP1 | Mps1-IN-2 | Ocifisertib（CFI-400945 free base） | SBE13 Hydrochloride
相关库: Anti-Liver Cancer Compound Library | Cell Cycle Compound Library | Kinase Inhibitor Library | Inhibitor Library | Epigenetics Compound Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | Highly Selective Inhibitor Library | Reprogramming Compound Library | Preclinical Compound Library
Bioactivity
英文名: LFM-A13
描述: LFM-A13 是一种 BTK，JAK2，PLK 有效抑制剂，可抑制 BTK、Plx1 和 PLK3 的活性，IC50分别为 2.5、10 和 61 μM。
体外活性: In BTK+ B-lineage leukemic cells, LFM-A13 enhances their sensitivity to ceramide- or vincristine-induced apoptosis. [1] In BCL-1 cells, NALM-6 cells, or normal BALB/c splenocytes, LFM-13 inhibits the enzymatic activity of BTK in BCL-1 cells without affecting the BTK protein expression levels [2] In human neutrophils, LFM-A13 decreases the tyrosine phosphorylation induced by fMet-Leu-Phe and inhibits the production of superoxide anions and the stimulation of adhesion, chemotaxis, and phospholipase D activity. [3]
体内活性: In BALB/c mice bearing BCL-1 leukemia, combination of LFM-A13 (50 mg/kg/day i.p.) and the standard triple-drug VPL prolongs the median survival time. [2] In primary myeloma-bearing SCID-rab mice, LFM-A13 inhibits osteoclast activity, prevents myeloma-induced bone resorption and suppresss myeloma growth. [4]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 67 mg/mL (186.1 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字: Janus kinase | JAK | LFM-A-13 | Inhibitor | LFMA13 | Polo-like Kinase (PLK) | Bruton tyrosine kinase | Btk | LFM A13 | inhibit | LFM-A13
相关产品: HMN-176 | MLN0905 | TAK-960 | Onvansertib | PHA-680632 | 7-O-Prenylscopoletin | 3MB-PP1 | Mps1-IN-2 | Ocifisertib（CFI-400945 free base） | SBE13 Hydrochloride
相关库: Anti-Liver Cancer Compound Library | Cell Cycle Compound Library | Kinase Inhibitor Library | Inhibitor Library | Epigenetics Compound Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | Highly Selective Inhibitor Library | Reprogramming Compound Library | Preclinical Compound Library
猜你喜欢
感兴趣产品